Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human single and multiple ascending dose study of BMS-986251 with food effect and bioavailability assessment
NL-OMON44577Phase 1Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of bms-986251 in psoriasis and autoimmune disease, sponsored by Bristol Myers Squibb. Started Oct 2017; status: active, not recruiting.
02
Drugs
bms-986251
03
Conditions
psoriasisautoimmune disease
Beyond the preview
Go deeper on NL-OMON44577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44577.